iRegene’s Parkinson’s therapy gains FDA designation
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
India in the Changing Landscape of Life-Sciences Research & Development
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated